Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancersChris Bryant, Andrew J. Massey|BMC Cancer|2014Cited by 110
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cellsChris Bryant, Andrew J. Massey|Molecular Cancer|2014Cited by 53
Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGICAndrew J. Massey|PLoS ONE|2015Cited by 46
Identification of novel,<i>in vivo</i>active Chk1 inhibitors utilizing structure guided drug designAndrew J. Massey, Mike Wood|Oncotarget|2015Cited by 44
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatmentsRebecca Rawlinson, Andrew J. Massey|BMC Cancer|2014Cited by 33